NICE Now Recommends Mindfulness-Based Cognitive Therapy as First-Line for Depression — Not Just Relapse Prevention

For two decades, mindfulness-based cognitive therapy occupied a specific niche in clinical guidelines: relapse prevention for patients with three or more depressive episodes. Useful, evidence-based, but narrow. If you were not already in remission, MBCT was not for you.

That has changed. NICE guideline NG222, published in June 2022, moved MBCT into a fundamentally different position. It is now recommended as a first-line treatment option for adults experiencing a new episode of less severe depression. Not as an add-on. Not as a last resort. As a frontline clinical intervention, positioned ahead of antidepressant medication in the decision hierarchy.

This is the moment mindfulness crossed from alternative to mainstream in British clinical policy.

What NICE Actually Recommends

The guideline addresses two distinct clinical scenarios.

New episodes of less severe depression. NICE recommends offering patients a choice between several first-line treatments. Group mindfulness and meditation (with MBCT named as the exemplar) sits alongside group CBT, group behavioral activation, individual CBT, individual behavioral activation, group exercise, and self-help with support. The committee concluded that psychological therapies were more effective than antidepressants for less severe depression, and that medication should not be the default unless the patient prefers it.

This is not a theoretical repositioning. It means MBCT should be available through NHS Talking Therapies as a treatment option offered to patients at the point of assessment. Practically, it means a patient presenting with less severe depression should hear "we can offer you group mindfulness-based cognitive therapy" as one of the first options discussed.

Relapse prevention in patients at higher risk. For patients who have remitted from depression but are assessed as being at higher risk of relapse, NICE recommends three options: continuing antidepressant medication, switching to group psychological therapy (MBCT or group CBT) for patients who wish to discontinue medication, or combining both. The evidence showed MBCT was at least as effective as maintenance antidepressants for preventing relapse — with the obvious advantage of no pharmacological side effects and no withdrawal challenges.

The Evidence Base

The committee's decision was grounded in cost-effectiveness analysis alongside clinical evidence. For less severe depression, group mindfulness and meditation demonstrated effectiveness comparable to other recommended psychological therapies and was cost-effective within the NHS framework. For relapse prevention, the evidence base draws on trials comparing MBCT head-to-head against maintenance antidepressants — most prominently the PREVENT trial and the Kuyken et al. (2015) individual patient data meta-analysis showing MBCT was as effective as antidepressants over a 60-week period.

A 2025 Lancet Psychiatry randomized controlled trial added a new dimension: MBCT was effective for patients who had not remitted after completing high-intensity psychological therapy through NHS Talking Therapies. This positions MBCT not only as a first-line option but as a viable rescue intervention when standard psychological treatments have not achieved remission.

The Quality Problem

Here is where clinicians must exercise caution. NICE recommends a specific clinical intervention: structured MBCT delivered in group format, typically 8 sessions over 2-3 months, with optional additional sessions over the following 12 months. The treatment is manualized. Therapists should be trained. The program follows Segal, Williams, and Teasdale's MBCT protocol.

This is not what most people mean when they say "mindfulness."

The corporate wellness industry has appropriated the term for something fundamentally different: app-based guided meditations, 10-minute sessions, no clinical oversight, no structured program, no therapeutic relationship. Headspace is not MBCT. Calm is not MBCT. A wellness afternoon at a tech company is not MBCT. The evidence supporting NICE's recommendation comes from structured clinical programs delivered by trained therapists. The evidence does not come from apps.

The risk of the NICE expansion is dilution. As mindfulness gains guideline-level credibility, the pressure to offer cheaper, shorter, less supervised versions will intensify. Commissioners may fund "mindfulness programs" that bear little resemblance to the 8-week clinical MBCT format the evidence supports. Clinicians have a responsibility to distinguish between the intervention and its commercially convenient imitations.

Clinical Takeaway

MBCT has arrived as a mainstream clinical intervention — first-line for less severe depression, equivalent to antidepressants for relapse prevention. This is no longer the domain of alternative therapy conferences. It is NHS guideline territory.

For your practice: if you are not already trained in MBCT delivery, consider it. If you refer patients for MBCT, verify the program follows the clinical protocol — 8 sessions, trained therapist, group format, structured curriculum. If a patient asks whether a meditation app counts, the answer is no. Clinical MBCT and consumer mindfulness products share a vocabulary. They do not share an evidence base.